FRI0364 Neuropsychiatric manifestations in juvenile systemic lupus erythematosus (JSLE)

IF 20.6 1区 医学 Q1 RHEUMATOLOGY Annals of the Rheumatic Diseases Pub Date : 2013-06-01 DOI:10.1136/ANNRHEUMDIS-2012-EULAR.2821
A. Lapa, M. Postal, N. Sinicato, L. Silveira, A. Ferrari, R. Marini, S. Appenzeller
{"title":"FRI0364 Neuropsychiatric manifestations in juvenile systemic lupus erythematosus (JSLE)","authors":"A. Lapa, M. Postal, N. Sinicato, L. Silveira, A. Ferrari, R. Marini, S. Appenzeller","doi":"10.1136/ANNRHEUMDIS-2012-EULAR.2821","DOIUrl":null,"url":null,"abstract":"Background The nervous system affects children and adults with systemic lupus erythematosus (SLE) and is associated with a worse prognosis and elevated mortality. In juvenil onset SLE (jSLE) the prevalence of neuropsychiatric manifestations is even more frequently observed when compared to adult onset SLE. Objectives To analyze the prevalence of neuropsychiatric manifestations in jSLE. Methods We conducted a retrospective study including all patients with jSLE followed by the pediatric rheumatology clinic of Unicamp with disease onset before 16 years of age. The neuropsychiatric manifestations were analyzed by reviewing medical records, according to the nomenclature and classification of the American College of Rheumatology (ACR). Neuropsychiatric manifestations were considered present at disease onset when they occurred in the first six months of disease and during evolution, when occurred after this period. Results We included 66 patients (62 women) with mean age of 17.77 years (SD ± 4.55). At disease onset, a total of 46 neuropsychiatric manifestations were observed in 35 (53.03%) patients. The manifestations more frequently observed at disease onset were: headache (42.42%), seizures (16.66%), psychosis (4.54%), depression (3.03%), acute confusional state (1.51%) and chorea (1.51%). During the follow-up period, 99 neuropsychiatric manifestations were observed in 46 (69.69%) patients. The neuropsychiatric manifestations more frequently observed were headache (43.93%), cognitive impairment (36.66%), anxiety (31.81%), depression (19.69%), seizures (7.57%), psychosis (3.03%), acute confusional state (3.03%), chorea (1.51%) and polyneuropathy (1.51%). Thirteen (19.69%) patients never had neuropsychiatric manifestations during the course of the disease and twenty-eight (42.42%) patients had recurrent neuropsychiatric manifestations. Six (9.09%) patients had recurrent seizures. There were no cases of transverse myelitis in this series. Conclusions The neuropsychiatric manifestations are frequently observed in patients with jSLE, however 20% of jSLE patients never had any neuropsychiatric manifestation during the follow-up period. Central nervous system manifestations were more frequently observed than manifestations affecting the peripheral nervous system. Most patients had recurrent neuropsychiatric manifestations. References ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608. Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. Clin Radiol. 2004;59:1061-1069. Appenzeller S, Vasconcelos FA, Li LM, Costallat LT, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol. 2008;64:635-643 Disclosure of Interest A. Lapa Grant/Research support from: FAPESP 2010/13639-1, M. Postal Grant/Research support from: FAPSEP 2009/10744-1, N. Sinicato Grant/Research support from: FAPESP 2010/13637-9, L. Silveira Grant/Research support from: FAPSEP 2010/11923-4, A. Ferrari Grant/Research support from: FAPSEP 2011/13905-6, R. Marini: None Declared, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4)","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"71 1","pages":"437 - 437"},"PeriodicalIF":20.6000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/ANNRHEUMDIS-2012-EULAR.2821","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ANNRHEUMDIS-2012-EULAR.2821","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background The nervous system affects children and adults with systemic lupus erythematosus (SLE) and is associated with a worse prognosis and elevated mortality. In juvenil onset SLE (jSLE) the prevalence of neuropsychiatric manifestations is even more frequently observed when compared to adult onset SLE. Objectives To analyze the prevalence of neuropsychiatric manifestations in jSLE. Methods We conducted a retrospective study including all patients with jSLE followed by the pediatric rheumatology clinic of Unicamp with disease onset before 16 years of age. The neuropsychiatric manifestations were analyzed by reviewing medical records, according to the nomenclature and classification of the American College of Rheumatology (ACR). Neuropsychiatric manifestations were considered present at disease onset when they occurred in the first six months of disease and during evolution, when occurred after this period. Results We included 66 patients (62 women) with mean age of 17.77 years (SD ± 4.55). At disease onset, a total of 46 neuropsychiatric manifestations were observed in 35 (53.03%) patients. The manifestations more frequently observed at disease onset were: headache (42.42%), seizures (16.66%), psychosis (4.54%), depression (3.03%), acute confusional state (1.51%) and chorea (1.51%). During the follow-up period, 99 neuropsychiatric manifestations were observed in 46 (69.69%) patients. The neuropsychiatric manifestations more frequently observed were headache (43.93%), cognitive impairment (36.66%), anxiety (31.81%), depression (19.69%), seizures (7.57%), psychosis (3.03%), acute confusional state (3.03%), chorea (1.51%) and polyneuropathy (1.51%). Thirteen (19.69%) patients never had neuropsychiatric manifestations during the course of the disease and twenty-eight (42.42%) patients had recurrent neuropsychiatric manifestations. Six (9.09%) patients had recurrent seizures. There were no cases of transverse myelitis in this series. Conclusions The neuropsychiatric manifestations are frequently observed in patients with jSLE, however 20% of jSLE patients never had any neuropsychiatric manifestation during the follow-up period. Central nervous system manifestations were more frequently observed than manifestations affecting the peripheral nervous system. Most patients had recurrent neuropsychiatric manifestations. References ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608. Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. Clin Radiol. 2004;59:1061-1069. Appenzeller S, Vasconcelos FA, Li LM, Costallat LT, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol. 2008;64:635-643 Disclosure of Interest A. Lapa Grant/Research support from: FAPESP 2010/13639-1, M. Postal Grant/Research support from: FAPSEP 2009/10744-1, N. Sinicato Grant/Research support from: FAPESP 2010/13637-9, L. Silveira Grant/Research support from: FAPSEP 2010/11923-4, A. Ferrari Grant/Research support from: FAPSEP 2011/13905-6, R. Marini: None Declared, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4)
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
青少年系统性红斑狼疮(JSLE)的神经精神表现
背景:神经系统影响儿童和成人系统性红斑狼疮(SLE)患者,并与较差的预后和较高的死亡率相关。在青少年起病的SLE (jSLE)中,神经精神表现的患病率甚至比成人起病的SLE更常被观察到。目的分析jSLE患者神经精神表现的患病率。方法我们进行了一项回顾性研究,纳入了所有发病年龄在16岁之前的Unicamp儿童风湿病诊所的jSLE患者。根据美国风湿病学会(ACR)的命名法和分类,通过回顾医疗记录分析神经精神表现。神经精神表现在发病前6个月被认为是存在的,在发病后6个月被认为是在进化过程中出现的。结果纳入66例患者,其中女性62例,平均年龄17.77岁(SD±4.55)。发病时,35例(53.03%)患者共出现46种神经精神表现。发病时以头痛(42.42%)、癫痫(16.66%)、精神错乱(4.54%)、抑郁(3.03%)、急性神志不清(1.51%)、舞蹈病(1.51%)为主。随访期间,46例(69.69%)患者出现99种神经精神表现。常见的神经精神表现为头痛(43.93%)、认知障碍(36.66%)、焦虑(31.81%)、抑郁(19.69%)、癫痫发作(7.57%)、精神病(3.03%)、急性精神错乱(3.03%)、舞蹈病(1.51%)和多发性神经病(1.51%)。13例(19.69%)患者在病程中无神经精神表现,28例(42.42%)患者有复发性神经精神表现。6例(9.09%)患者反复发作。本系列病例中无横贯性脊髓炎病例。结论jSLE患者常出现神经精神表现,但20%的jSLE患者在随访期间未出现任何神经精神表现。中枢神经系统的表现比周围神经系统的表现更常见。多数患者有复发性神经精神表现。参考文献ACR狼疮神经精神命名特设委员会。美国风湿病学会神经精神性狼疮综合征的命名法和病例定义。风湿病。1999;42:599-608。李立民,李立民,陈建军。医学图像的纹理分析。中华放射医学杂志。2004;59:1061-1069。Appenzeller S, Vasconcelos FA, Li LM, Costallat LT, Cendes F.系统性红斑狼疮患者高白质病变的定量磁共振成像分析及临床意义。A. Lapa基金/研究支持来自:FAPESP 2010/13639-1, M. Postal基金/研究支持来自:FAPSEP 2009/10744-1, N. Sinicato基金/研究支持来自:FAPESP 2010/13637-9, L. Silveira基金/研究支持来自:FAPSEP 2010/11923-4, A. Ferrari基金/研究支持来自:FAPSEP 2011/13905-6, R. Marini: None Declared, S. Appenzeller基金/研究支持来自:FAPESP 2008/02917-0;巴西国家环境保护委员会(300447/2009-4)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases 医学-风湿病学
CiteScore
35.00
自引率
9.90%
发文量
3728
审稿时长
1.4 months
期刊介绍: Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.
期刊最新文献
Seasonality of IgG4-related disease. Immune endotypes and treatment response in psoriatic arthritis. Cracking the code of therapeutic failure in inflammatory rheumatic diseases: collaborative pathways bridging academia, industry, and patient-centric innovation. A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis. Beyond the scales: time to prioritise treatment of obesity in psoriatic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1